Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:BNTC NASDAQ:DMAC NASDAQ:LXEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.98+2.1%$2.10$1.33▼$3.16$93.32M0.7486,017 shs38,716 shsBNTCBenitec Biopharma$13.84+0.9%$12.99$8.49▼$17.15$363.31M0.4141,451 shs39,892 shsDMACDiaMedica Therapeutics$7.07+1.0%$6.00$3.19▼$7.49$365.44M1.4463,412 shs229,505 shsLXEOLexeo Therapeutics$6.62-1.2%$5.16$1.45▼$11.72$357.49M1.66779,511 shs448,657 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+1.02%-7.48%+5.04%-16.81%BNTCBenitec Biopharma0.00%+1.02%-1.14%+5.33%+35.69%DMACDiaMedica Therapeutics0.00%+1.87%+31.66%+93.70%+58.88%LXEOLexeo Therapeutics0.00%-2.22%+33.20%+49.44%-24.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.98+2.1%$2.10$1.33▼$3.16$93.32M0.7486,017 shs38,716 shsBNTCBenitec Biopharma$13.84+0.9%$12.99$8.49▼$17.15$363.31M0.4141,451 shs39,892 shsDMACDiaMedica Therapeutics$7.07+1.0%$6.00$3.19▼$7.49$365.44M1.4463,412 shs229,505 shsLXEOLexeo Therapeutics$6.62-1.2%$5.16$1.45▼$11.72$357.49M1.66779,511 shs448,657 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+1.02%-7.48%+5.04%-16.81%BNTCBenitec Biopharma0.00%+1.02%-1.14%+5.33%+35.69%DMACDiaMedica Therapeutics0.00%+1.87%+31.66%+93.70%+58.88%LXEOLexeo Therapeutics0.00%-2.22%+33.20%+49.44%-24.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.60Moderate Buy$7.00253.54% UpsideBNTCBenitec Biopharma 2.89Moderate Buy$24.8079.19% UpsideDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3374.45% UpsideLXEOLexeo Therapeutics 2.71Moderate Buy$15.33131.62% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, LXEO, BNTC, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ADAGAdageneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BNTCBenitec BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LXEOLexeo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$20.009/16/2025BNTCBenitec BiopharmaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$35.00 ➝ $29.008/15/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/15/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/15/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.008/15/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $9.008/6/2025ADAGAdageneLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K933.17N/AN/A$1.14 per share1.74BNTCBenitec Biopharma$80K4,541.25N/AN/A$3.71 per share3.73DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ALXEOLexeo Therapeutics$650K549.97N/AN/A$3.53 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/AN/ABNTCBenitec Biopharma-$37.92M-$1.47N/AN/AN/AN/A-46.19%-43.88%11/13/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)Latest ADAG, LXEO, BNTC, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025BNTCBenitec Biopharma-$0.24-$0.42-$0.18-$0.42N/AN/A8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdageneN/A2.29N/ABNTCBenitec Biopharma0.0154.6754.67DMACDiaMedica TherapeuticsN/A7.557.55LXEOLexeo TherapeuticsN/A4.434.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%BNTCBenitec Biopharma52.19%DMACDiaMedica Therapeutics10.12%LXEOLexeo Therapeutics60.67%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%BNTCBenitec Biopharma1.30%DMACDiaMedica Therapeutics7.30%LXEOLexeo Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.13 million37.14 millionNot OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionableADAG, LXEO, BNTC, and DMAC HeadlinesRecent News About These CompaniesPalumbo Wealth Management LLC Invests $226,000 in Lexeo Therapeutics, Inc. $LXEOSeptember 26, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $15.33 Average Target Price from AnalystsSeptember 24, 2025 | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesSeptember 19, 2025 | marketbeat.comLexeo Therapeutics, Inc. $LXEO Shares Sold by Adage Capital Partners GP L.L.C.September 10, 2025 | marketbeat.comIs Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?August 29, 2025 | finance.yahoo.comInsider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of StockAugust 21, 2025 | insidertrades.comLexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy DesignationAugust 20, 2025 | msn.comLexeo Therapeutics price target lowered to $15 from $20 at ChardanAugust 16, 2025 | msn.comLexeo Therapeutics reports Q2 EPS (60c) vs (64c) last yearAugust 14, 2025 | msn.comLexeo Therapeutics Appoints New Chief Financial OfficerAugust 14, 2025 | tipranks.comLexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 14, 2025 | globenewswire.comOppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform RecommendationAugust 1, 2025 | msn.comStifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)July 29, 2025 | msn.comLexeo Therapeutics Holds 2025 Annual Stockholders MeetingJuly 25, 2025 | theglobeandmail.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - MorningstarJuly 8, 2025 | morningstar.comMLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - NasdaqJuly 8, 2025 | nasdaq.comWhy Lexeo Is Rising In Pre-market? - NasdaqJuly 8, 2025 | nasdaq.comLexeo Therapeutics stock rises after FDA breakthrough designationJuly 8, 2025 | au.investing.comLexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy DesignationJuly 8, 2025 | msn.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich AtaxiaJuly 7, 2025 | globenewswire.comLexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.comJuly 2, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAG, LXEO, BNTC, and DMAC Company DescriptionsAdagene NASDAQ:ADAG$1.98 +0.04 (+2.06%) Closing price 10/3/2025 03:55 PM EasternExtended Trading$1.99 +0.01 (+0.56%) As of 10/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Benitec Biopharma NASDAQ:BNTC$13.84 +0.12 (+0.87%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$14.17 +0.33 (+2.41%) As of 10/3/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.DiaMedica Therapeutics NASDAQ:DMAC$7.07 +0.07 (+1.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.00 -0.07 (-0.98%) As of 10/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Lexeo Therapeutics NASDAQ:LXEO$6.62 -0.08 (-1.19%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.59 -0.03 (-0.44%) As of 10/3/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
